Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-a...
Alternative Titles
Full title
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9cfb1fdb9f6c430db872bd8a928dcb95
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9cfb1fdb9f6c430db872bd8a928dcb95
Other Identifiers
ISSN
1741-7015
E-ISSN
1741-7015
DOI
10.1186/1741-7015-9-36
